NEW YORK HEART INSTRUMENTS, INC. SEEKING CLASS II STATUS FOR MODEL FFF-IA EKG
This article was originally published in The Gray Sheet
Executive Summary
NEW YORK HEART INSTRUMENTS, INC. SEEKING CLASS II STATUS FOR MODEL FFF-IA EKG device when labeled for "aiding physicians in making an early, noninvasive detection of coronary artery disease." In a recent petition, the company asks FDA to reconsider its decision to deny a 510(k) for the electrocardiogram device; the agency's conclusion was based on a determination that the product has a new indication that requires regulation in Class III.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.